Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials

Semaglutide is a glucagon-like peptide-1 (GLP-1) analog treatment for type 2 diabetes (T2D) available in subcutaneous (s.c.) and oral formulations. Two cardiovascular (CV) outcomes trials showed that in subjec...

Source: Cardiovascular Diabetology - September 30, 2020 Category: Cardiology Authors: Mansoor Husain, Stephen C. Bain, Anders Gaarsdal Holst, Thomas Mark, S øren Rasmussen and Ildiko Lingvay Tags: Original investigation Source Type: research